12:20 PM
 | 
Nov 09, 2017
 |  BC Extra  |  Company News

FDA approves Merck's Prevymis for CMV

FDA approved once-daily oral and IV formulations of Prevymis letermovir (MK-8228) from Merck & Co. Inc. (NYSE:MRK) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation (HSCT).

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >